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Abstract: For lupus nephritis (LN) management, it is very important to detect fibrosis at an early
stage. Urinary exosomal miRNAs profiling can be used as a potential multi-marker phenotyping
tool to identify early fibrosis. We isolated and characterised urinary exosomes and cellular pellets
from patients with biopsy-proven LN (n = 45) and healthy controls (n = 20). LN chronicity index
(CI) correlated with urinary exosomal miR-21, miR-150, and miR-29c (r = 0.565, 0.840, −0.559,
respectively). This miRNA profile distinguished low CI from moderate-high CI in LN patients with a
high sensitivity and specificity (94.4% and 99.8%). Furthermore, this multimarker panel predicted
an increased risk of progression to end-stage renal disease (ESRD). Pathway analysis identified
VEGFA and SP1 as common target genes for the three miRNAs. Immunohistochemistry in LN renal
biopsies revealed a significant increase of COL1A1 and COL4A1 correlated with renal chronicity.
SP1 decreased significantly in the high-CI group (p = 0.002). VEGFA levels showed no differences.
In vitro experiments suggest that these miRNA combinations promote renal fibrosis by increasing
profibrotic molecules through SP1 and Smad3/TGFβ pathways. In conclusion, a urinary exosomal
multimarker panel composed of miR-21, miR-150, and miR-29c provides a non-invasive method to
detect early renal fibrosis and predict disease progression in LN.
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1. Introduction
Fibrosis, or tissue scarring, is the result of an excessive, persistent, and destructive accumulation
of extracellular matrix components (ECM) in response to chronic tissue injury in the kidney. Renal
fibrosis represents the final stage of most chronic kidney diseases and contributes to a progressive and
irreversible decline in kidney function. The continuous accumulation of ECM causes a disruption
of the epithelium and/or endothelium integrity that results in the activation of a complex cascade
of molecular and cellular events [1]. Initially, there is an inflammatory response with the release of
profibrotic cytokines, chemokines, and growth factors, which in turn promote the proliferative phase of
the scarring process characterised by the recruitment and activation of fibroblasts into ECM-secreting
myofibroblasts and the formation of a permanent fibrotic scar [2,3].
Lupus nephritis (LN) occurs in ~40–75% of systemic lupus erythematosus (SLE) patients [4] and
continues to be one of the major causes of morbi-mortality in those patients. Despite improvements
in its management, up to 20% of patients will progress to end-stage renal disease (ESRD) [5]. So far,
renal biopsy continues to be the gold-standard technique to evaluate the degree of fibrosis, but its
invasiveness makes it unsuitable for serial monitoring [6]. Detection of early stages of fibrosis could
contribute to identify patients at risk of progressing to ESRD who can benefit from new therapeutic
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approaches. Therefore, there is the need to identify non-invasive biomarkers to detect early fibrosis
and to monitor its progression.
Urine samples are obtained relatively easily and cost-efficiently compared with other biological
samples such as blood, cerebrospinal fluid, or tissue biopsy. The analysis of urinary miRNAs provides
a measure of the health of the excretory system and is detected noninvasively from urinary cellular
pellet or inside urinary exosomes [7]. Most studies use urinary cellular pellet for study of miRNA
expression [8–10]. In recent years, urinary exosomes gathered strength in the field of biomarkers due
to being small membranous vesicles secreted by a variety of living cells and implicated in cell-to-cell
communication [11,12]. Inside them, there are small non-coding RNAs, the miRNAs, which regulate
many molecular and cellular processes by repressing translation or causing breakdown in target
gene mRNAs [13]. Urinary exosomal miRNAs can accurately reflect renal dysfunction and structural
damage, making them good targets for the exploration of biomarkers for urinary tract diseases [14,15].
miRNA expression profiling in renal fibrosis has been evaluated in kidney tissue samples [16],
blood [17], and urine [18] from various chronic kidney diseases. Despite a large number of miRNAs
being identified, a recent meta-analysis study only showed seven of them to be highly related to
fibrosis [19]. Of those, miR-29c, miR-21, and miR-200a, regulators of the TGF-β/Smad3 signalling
pathway, have been described in urinary exosomes [20–23]. Furthermore, three miRNAs have been
associated with renal fibrosis in LN patients: miR-410, which contributes to renal fibrosis by inhibiting
interleukin-6 [24], miR-29c as predictor of early renal fibrosis [25], and miR-150, which promotes renal
fibrosis by downregulation of SOCS1 [26].
Unfortunately, it is now generally accepted that single markers do not achieve sufficient sensitivity
and specificity for diagnosis and routine clinical practices. A novel trend based on the combination of
several signatures has improved clinical performance [27–29]. In this study, we compared miR-29c,
miR-200a, miR-21, miR-410, and miR-150 expression levels between urinary pellet and exosomes. Then,
we estimated a combinatory panel of urinary exosome-derived miRNAs from active LN patients to
identify early fibrosis and predict progression to ESRD.
2. Materials and Methods
2.1. Patients and Samples
Patients with biopsy-proven active LN were recruited from the Lupus Unit at Vall d’Hebron
Hospital (N = 45). The study was ethically approved by Vall d’Hebron Hospital Ethics Committee
and all patients provided written informed consent prior inclusion. All patients fulfilled at least 4
of the American College of rheumatology (ACR) revised classification criteria for SLE [30]. Healthy
donors were used as controls (N = 20). Repeated renal biopsy was performed if required according to
clinical protocol (N = 7). Urine samples were collected from each patient 1 day before renal biopsy
and processed immediately to be stored at −80 ◦C (more details in SI). SLE disease activity was
assessed by the SLE Disease Activity Index 2000 update (SLEDAI-2Ks; range 0–105) [31]. Patients were
classified according to the chronicity index (CI) at renal biopsy: Low CI (<2, N = 18), moderate CI (2–4,
N = 21), and high CI (≥4, N = 6). ESRD progression was defined by an estimated glomerular filtration
rate (eGFR) <15 mL/min/1.73 m2, the initiation of renal replacement therapy or receiving kidney
transplantation, or 40% reduction of baseline eGFR [32]. Estimated glomerular filtration ratio (eGFR)
was calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula [33].
2.2. Renal Histology and Immunohistochemistry
Renal biopsies were examined by light and immunofluorescence microscopy following standard
methods and categorised according to the International Society of Nephrology/Renal Pathology
Society classification (2003) [34] and rated for activity (AI) and chronicity (CI) [35]. Renal
chronicity was measured by Gömöri trichrome staining from paraffin-embedded renal samples.
For immunohistochemistry, rabbit anti-VEGF-A antibody (Abcam, ab46154, dilution of 1:50) and a
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diaminobenzidine (DAB) chromogen kit (DAKO) were used. Histology and immunohistochemistry
samples were blinded and scored by the Vall d’Hebron pathologist unit (more details in SI).
2.3. Exosome and Pellet Purification and Characterisation
Fresh urine samples (50 mL) to obtain the urinary cellular pellet and supernatant were centrifuged
at 3900× g for 30 min and kept for urinary exosome isolation. Following the manufacturer’s instructions,
urinary exosomes were isolated using the miRCURY™ Exosome Isolation Kit—Cells, urine and CSF
(Exiqon, Woburn, Massachusetts, USA). In order to validate the exosome purification protocol, urinary
exosome morphology, shape, and size were analysed by Cryo-transmission electron microscopy.
NanoSight and Western blot analysis were used to characterise exosome isolation (more details in SI).
Quantification of Urinary exososmes was performed byFluorCet Exosome Quantitation Kit (SBI, more
details in SI) according to the manufacturer’s instructions.
2.4. RNA Isolation from Urinary Cell Pellet and Exosomes
RNA from urinary pellets or exosomes were extracted using the miRCURY™RNA Isolation Kit-Cell
& Plant (Exiqon, Woburn, MA, USA, more details in SI), following the manufacturer’s instructions.
Quantification and evaluation of the RNA quality was assessed by Bioanalyzer PicoChip analysis.
2.5. Individual Assay qPCR-RT
Initially a first-strand cDNA synthesis reaction was made to provide a template for all microRNA
real-time PCR assay using the miRCURY LNA™ Universal RT microRNA PCR (Exiqon, Woburn,
MA, USA, more details in SI). MiRNAs were quantified with specific miRCURY LNA primer set
and ExiLENT SYBR Green master mix (Exiqon, Table S1) using the ABI PRISM 7000 following the
manufacturer’s instructions. Data were normalised based on the expression of RNU6 and relative
quantification was calculated (RQ = 2−∆∆Ct) using the Livak method [36].
2.6. Pathway Analysis
To gain insight into the functions of miRNA target genes, we performed gene ontology (GO)
classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
using the online tools of DNA ntelligent Analysis (DIANA)-miRPath v3.0 software [37]. To present the
regulation between miRNA and gene, experimentally validated targets were extracted for identified
miRNAs from miRTarBase [38] and critical miRNA–target interactions were constructed using miRNet
(www.mirnet.ca) [39].
2.7. Immunofluorescence in Renal Biopsy
Immunofluorescence was performed on paraffin-embedded (FFPE) renal biopsies during renal
flare (N = 3 for each subgroup) following the protocol described by Mason et al. [40]. Staining was
performed with 1:50 rabbit anti-SP1 (Abcam, ab124804), 1:100 mouse anti-COL1A1 (Abcam, ab6308),
or 1:100 mouse anti-COL4A1 (Abcam, ab6311) overnight at 4 ◦C (more details in SI).
2.8. Human Kidney Cells Culture
Primary human renal mesangial cells (RMCs) and renal tubular epithelial cells (RTCs) were
purchased from InnoProt (Derio, Spain) and cultured in the recommended media provided by the
manufacturer. Cells were grown at 37 ◦C in a humidified 5% CO2 atmosphere. Cell passes were
performed using TrypLE™ Express (Gibco® ThermoFisher Scientific, Waltham, MA, USA).
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2.9. Overexpression of miR-21/miR-150 and Inhibition of mir-29c in Human Kidney Cells
Cells plated on 24-well plates were transfected with mimic miR-21 and mimic miR-150
(ThermoFisher Scientific, Waltham, MA, USA) or with miR-29c inhibitor (ThermoFisher Scientific,
Waltham, MA, USA) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions. After 48 h, cells were stimulated with TGFβ1 citokine (10 ng/mL,
ThermoFisher Scientific, Waltham, MA, USA). After 24 h, the total RNA was extracted using miRCURY
RNA Isolation Kit (Exiqon, Woburn, MA, USA) or the immunofluorescence was performed (more
details in SI, Table S2).
2.10. Luciferase Activity Analysis
Human kidney cells were plated in 96-well plates for 24 h and then were cotransfected using
DharmaFECT Duo transfect reagent (ThermoFisher Scientific, Waltham, MA, USA) with 40 ng of
pEZX-MT06-SP1 3′UTR plus 10 nM of miR-21, miR-150, or miR-29c analog or miR negative control
(5 duplicates per group). The pEZX-MT06-SP1 3′UTR plasmid contains firefly luciferase and miR
binding site from SP1 3′UTR, which is inserted between firefly luciferase cDNA and PolyA (more
binding site details in Figure S1). This plasmid also includes Renilla luciferase as an internal control
(GeneCopoeia, Rockville, MD, USA). Transfected cells were lysed by reporter lysis buffer (Promega,
Madison, WI, USA). Dual luciferase activity was measured with the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI, USA) by FLUOstar Omega (BMG Labtech, Oternberg, Germany).
2.11. Statistical Analysis
Statistical analyses were performed by GraphPad Prism version 6 (GraphPad Software, La Jolla,
CA, USA) and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). The mean expression of miRNA
levels was compared using Mann–Whitney U/Kruskal–Wallis H tests, as appropriate. The relationship
between miRNA expression and histological/clinical parameters of LN patients were analysed using
the Spearman correlation coefficient. Risk of progression to ESRD and renal survival rate across urinary
exosomal miRNAs were analysed and compared using the Kaplan–Meier analysis and the log-rank
test. The diagnostic performance of biomarkers was evaluated by calculating their sensitivity and
specificity using receiver operating characteristic (ROC) curves. A combinatorial analysis of multiple
biomarker signatures was carried out using the CombiROC method [41] (more details in SI).
3. Results
3.1. Patients
Patient demographic characteristics and laboratory measurements are summarised in Table 1.
Most patients included had a type IV GMN and had a moderate chronicity index degree (N = 21) at
inclusion (Figure S2). No significant clinical differences were observed between subgroups such as age,
gender, serum creatinine, proteinuria, blood urea nitrogen (BUN), and eGFR (Table 1). Patients were
followed up for a median of 8 years (range: 3.5 to 12.5) after renal biopsy.
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Table 1. Clinical and laboratory characteristics of the study subjects.
Characteristics
Lupus Nephritis (n = 45)
Healthy Control
(n = 20)Low CI (N = 18) Moderate CI(N = 21) High CI (N = 6)
Demographic
Age, year 33 ± 7 29 ± 5 30 ± 4 28 ± 5
Sex, male/female 7/11 8/13 3/3 8/12
Race/ethnicity, n (%)
Caucasian 18 20 6 19
Hispanic 0 1 0 1
Laboratory Parameters
Serum creatinine, mg/Dl 0.9 ± 0.3 1.1 ± 0.8 1.1 ± 0.6 0.7 ± 0.2
eGFR (mL/min) 92.3 ± 26.7 78.6 ± 29.3 78.8 ± 42.6 97.2 ± 31.7
BUN (mmol/l) 4.7 ± 1.2 4.6 ± 2.9 4.3 ± 1.7 5.0 ± 1.5
Anti-dsDNA Abs, IU/mL 333 ± 104 343 ± 107 357 ± 143 n.d.
Serum C3, mg/dL 69.5 ± 16.1 87.5 ± 12.1 74.5 ± 16.1 n.d.
Serum C4, mg/dL 8.3 ± 2.1 10.4 ± 3.5 11.2 ± 2.7 n.d.
Proteinuria, g/24 h 4.2 ± 2.4 3.6 ± 2.5 3.9 ± 4.7 n.d.
Disease Index (SLEDAI-2K)
Total SLEDAI score 18 ± 2 14 ± 2 16 ± 3 n.d.
Renal Biopsy, n (%)
Class, n (%)
III 4 6 0 n.d.
IV 14 12 4 n.d.
V 0 3 1 n.d.
Activity Index 6.3 ± 3.7 5.3 ± 4.1 6.3 ± 3.2 n.d.
Chronicity Index 0.6 ± 0.4 3.5 ± 0.5 5.8 ± 1.2 n.d.
Values are means ± SE. BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; anti-dsDNA,
anti-double-stranded DNA; n.d., not determinate.
3.2. Isolation and Characterization of Urinary Exosomes and Cellular Pellet
Urinary exosomes and pellets were isolated as described in the methodology. Exosomes were
examined using cryo-transmission electron microscopy, nanoparticle tracking, and Western blot
analysis. Results revealed vesicles of 85.5 ± 33.4 nm diameter with the characteristic cup-shaped
exosome morphology and the presence of the urinary exosome TSG101 protein (Figure 1A). The
number of urinary exosomes was similar among the different LN groups (mean 2.3 × 107, Figure S3).
The urinary cellular pellet was confirmed by the negativity of TSG101 protein, confirming the absence
of contamination from other cellular compartments.
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Figure 1. Characterisation of urinary exosomes and expression levels of urinary exosomal miR-21,
miR-150, miR-410, and miR-29c in lupus nephritis (LN) patients’ urinary pellets. (A) Cryo-transmission
electron micrograph, nanoparticle tracking analysis and Western blotting of TSG101 protein confirmed
that the isolated small vesicles are urinary exosomes (size of 52–119 nm in diameter). P1–P3: Pellet
urinary samples. E1–E3: Exosome urinary samples. C-: Negative control. (B) Values of miRNAs
expression from healthy controls and LN patients at flare time were represented as individual dots.
(C) Values of miRNAs expression when LN patients were classified according to the chronicity index
at renal biopsy (low CI (<2, N = 18), moderate CI (2–4, N = 21), high CI (≥4, N = 6)). Values were
normalised using RNU6 and fold change was calculated over healthy control group. * p < 0.05,
** p < 0.005, and *** p < 0.0005.
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3.3. miR-29c, miR-200a, miR-21, miR-410, and miR-150 Expression Levels Measured by Quantitative Reverse
Transcription-Polymerase Chain Reaction (qPCR-RT) in Urinary Exosomal Preparations and Cellular Pellet
A deep sequencing analysis was performed to compare the miRNA composition in the urinary
exosomes and cellular pellets obtained from three patients with LN (Table S3). The highest percentage
of miRNA was extracted from exosomes compared with the cell pellet (total reads 41,994,100 vs.
15,545,900, Figure S4A), suggesting that there is an enrichment of miRNA in exosomes. Next, we
compared the expression levels of the five miRNAs (miR-29c, miR-200a, miR-21, miR-410, and miR-150)
in urinary exosomes and cell pellet using qPCR-RT. Expression levels of the study miRNAs were only
detected in urinary exosomes (Figure S4B). For these reasons, we decided to focus on urinary exosomes
as the source to identify miRNA biomarkers for LN renal fibrosis.
We found miR-21 and miR-150 to be significantly overexpressed in the LN group compared with
healthy controls (6.6- and 2.3-fold change, respectively) and miR-410 and miR-29c to be significantly
reduced (−1.8- and −2.2-fold change, respectively, Figure 1B). No significant differences were observed
in miR-200a-3p expression levels (Figure S5). When results were evaluated according to the CI
subgroups, miR-410 expression levels did not differ between subgroups (Figure S6). However,
miR-21-5p, miR-150, and miR-29c were strongly correlated with renal chronicity (r = 0.565, r = 0.840,
and r = −0.559, respectively, Figure S7). Both miR-21 and miR-150 expression levels increased
progressively according to the degree of CI, being most highly expressed in the high CI group (13.3-
and 4.8-fold change, respectively). However, miR-29c showed a progressive downregulation, being
the lowest expression levels found in the high CI group (−18.7-fold change, Figure 1C). No correlations
were found between miR-21, miR-150, and miR-29c with traditional clinical parameters of damage
progression, such as serum creatinine levels, proteinuria or eGFR, and the activity index score. However,
significant correlation was found with tubular atrophy, interstitial fibrosis, glomerular sclerosis, and
fibrous crescent (p < 0.05, Figures S8–S11).
3.4. CombiROC Performance Analyses for Optimal Marker Combinations
We next tested miR-21, miR-150, and miR-29c prognostic value for the early detection of renal
fibrosis in LN. The diagnostic/prognostic accuracy of individual and of multiple marker combinations
was calculated by uploading the original data of analyte concentrations to the CombiROC tool. A test
cut off value of 1.80 (control mean + 3SD) was used. All possible marker combinations to distinguish
low CI from moderate-high CI group were obtained separately by setting the minimum sensibility and
specificity values in the next step and finally the best performing individual markers and combinations
were obtained via ROC analysis (Figure 2A,B).
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Figure 2. Correlation of urinary miRNAs with chronicity index and risk of end-stage progression
disease (ESRD). (A) Receiver operating characteristic (ROC) curve analysis of individual urinary
exosomal miR-29c, miR-21, and miR-150 expression to distinguish low CI group from moderate-high
CI group. Opt cutoff: Optimal cutoff according Youden’s index. (B) Multiple ROC curves showed that
miR-29c/miR-21/miR-150 multimarker panel has the best ROC curve profile. They were obtained using
CombiROC online program. eGFR: Estimated glomerula filtration rate. (C) Kaplan–Meier curve of
renal survival rate stratified by urinary exosomal miRNAs multimarker panel. There were significant
differences of the renal survival rate between positive and negative patients to multimarker panel by
the long-rank test. (D) Relative expression levels of miR-150, miR-21, and miR-29c were evaluated in
seven patients with two kidney renal biopsies. Values were normalised using RNU6. * p < 0.05.
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As an individual biomarker, miR-150 had the best profile to distinguish the two CI groups
(AUC = 0.970, cut-off > 0.903 with 96% sensibility and 83% specificity) whereas miR-21 ROC curve
was the least predictive (AUC = 0.742, cut-off > 4.15 with 81% sensibility and 72% specificity). ROC
analysis of other clinical parameters such as creatinine, eGFR, or proteinuria levels as predictors of
early renal fibrosis did not show better predictive value (Figure 2B).
Interestingly, the multimarker panel of miR-29c/mir-150/miR-21 expression levels exhibited the
highest sensitivity and specificity values (94.4% and 99.8%, AUC = 0.996, respectively, Figure 2B). The
pie chart of three miRNAs multimarker panel shows a low percentage of false positive cases for this
model (Figure S12).
We further investigated whether the combinatory multimarker panel could predict disease
progression in LN. Kaplan–Meier survival analysis showed that multimarker positive LN patients
(miR-29c/miR-150/miR-21) had 5- and 10-year renal survival rates of 73.6% and 63.2%, respectively,
in contrast with 100% and 89.4% for negative patients. The difference in renal survival rate was
statistically significant according to log-rank test (Figure 2C, p = 0.027).
Seven patients had a repeated biopsy in a median time of 23.8 months (range from 12 to 96 months)
(Table S4). We observed a significant increase in miR-21 and miR-150 expression levels (2.7- and 3.1-fold
change, respectively) and miR-29c reduction (−6.2-fold change, p < 0.05, Figure 2D) between baseline
and repeated samples that correlated with a CI increase.
3.5. Pathway Enrichment Analyses
We next hypothesised the biological pathways those selected miRNAs may regulate by targeting
multiple pathway-specific mRNAs. For each miRNA, we retrieved validated targets from miRTarBase,
(Table S5). An interaction network was constructed using miRNet (Figure 3A). Only two mRNAs were
common to the three miRNAs, SP1 and VEGFA. Since LN patients with renal fibrosis overexpressed
miR-150 and miR-21 but downregulated miR-29c, we also performed GO and KEGG pathway
enrichment analysis using miRPath (p value < 0.01, Figure 3B). Significant enrichment of target genes
was detected for seven functional GO pathways associated with extracellular matrix and collagen
formation (Figure 3B). In KEGG pathway analysis, three pathways were detected where ECM-receptor
interaction was the most significant (Figure 3B). The predicted interactions of this pathway showed
that COL1A1 and COL4A1 were one of the most significant modified mRNA genes common for the
three miRNAs (Table S6).
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Figure 3. Role of urinary exosomal miRNAs in LN renal fibrosis formation. (A) Venn diagram
representing overlap of validated targets of miR-29c-3p, miR-150-5p, and miR-21-5p. Network of
miRNA–target interaction was obtained using miRNet tool. (B) Enriched gene ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using DIANA miRPatch v3.0 software.
We focus in pathways with downregulation of miR-29c and upregulation of miR-150 and miR-21.
GO: Gene Ontology. KEGG: Kyoto Encyclopedia of Genes and Genomes. CI: chronicity index. (C)
Immunofluorescence of SP1 (green), COL1A1 and COL4A1 (red) in renal biopsy from LN chronicity
subgroups (low CI, moderate CI, and high CI). DAPI staining was used to label cell nuclei. Scale bar =
100 µm. DAPI: 4’,6-diamidino-2-phenylindole. (D) Cotransfection of miR-21, miR-150, or Mir-29c and
SP1 3’ UTR luciferase reporter significantly decreases the luciferase activity compared with miR-control
(five replicates per group). MRC: Renal mesangial cells; TRC: Renal tubular cells. * p < 0.05, ** p < 0.005,
and *** p < 0.0005.
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3.6. Confirmation of SP1 as Common Urinary miRNAs Target and Associated Profibrotic Molecules in Kidney
Biopsies
Next, we sought to confirm the pathway analysis in the kidney biopsies from LN patients. Therefore,
we examined the protein levels of SP1 and VEGFA in the different CI subgroups. Immunohistochemical
staining of VEGFA in the glomeruli was similar in all LN groups (Figure S13). However, high tubular
staining of SP1 protein was observed in low and moderate CI patients but SP1 decreased significantly
in high CI patients (p = 0.004 and 0.002, respectively, Figure 3C). COL1A1 and COL4A1 proteins were
predominantly localised in the tubular epithelial cells and extracellular matrix, increasing the staining
progressively with the degree of chronicity (Figure 3C).
To confirm SP1 as a target for the three studied miRNAs, we performed luciferase assay studies
using primary human renal mesangial cells (RMCs) and renal tubular epithelial cells (RTCs). We
co-transfected RMCs and RTCs with a plasmid containing a luciferase gene under the control of SP1
3′ untranslated region (UTR) and with either miR-29c, miR-150, or miR-21 analogue. MiR analogue
negative was used as control. Luciferase activity decreased in RMCs by 41.2%, 63.9%, and 54.9%
48 h after the transfection in the presence of miR-29c, mir-150, and miR-21 analogue compared with
the negative control, respectively (Figure 3D). In RTCs, the luciferase activity reduction was more
pronounced in all the three (68.8%, 66.8%, and 67.9%, respectively, Figure 3D).
3.7. Over-Expression of miR-21-5p/miR-150 and Inhibition of miR-29c Increase Profibrotic Proteins
In order to better investigate the roles of miR-21/miR-150/miR-29c in LN renal fibrosis formation,
we overexpressed both miR-21/miR-150 and inhibited miR-29c in TGFβ-stimulated RMCs and RTCs.
Overexpression of miR-21/miR-150 under TGFβ-stimulated RMCs induced a significant reduction of
SP1 expression (−3.8-fold change) whereas no changes in expression levels were observed with miR-29c
inhibition in this cell type (Figure 4A). The overexpression of miR-21/Mir-150 or the inhibition of
miR-29c induced COL4A1 formation via Smad3/TGFβ pathway (3.8- and 4.6-fold change, respectively,
Figure 4A).
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Figure 4. Overexpression of miR-21/miR-150 and inhibition of miR-29c increase profibrotic proteins.
(A) Quantitative real-time RT-PCR analysis shows the relative mRNA levels of SP1, COL1A1, COL4A1,
TGFβ, Smad3 in TGFβ-stimulated renal mesangial cells (RMCs) and renal tubular epithelial cells (RTCs).
Values were normalised using GADPH and fold change was calculated over control condition (mimic
miR-control or anti miR-control). (B) Immunofluorescent staining exhibits COL1A1 expression in
MRCs and TRCs with overexpression of miR-21/miR-150 and inhibition of miR-29c. SP1 staining was
inhibited completely with the overexpression of miR-21/miR-150 in both type of cells. Scale bar =
50 µm. * p < 0.05, ** p < 0.005, and *** p < 0.0005. (C) Proposed mechanism for urinary exosomal
miRNAs in early and later stages of LN renal fibrosis.
However, overexpression of SP1 was only observed in miR-29c-inhibited RTCs along with an
increased expression of the study profibrotic molecules. Overexpression of miR-21/miR-150 in RTCs
induced a significant reduction in SP1 expression levels, whereas COL1A1, COL4A1, TGFβ, and Smad3
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were significantly increased suggesting a Smad3/TGFβ fibrosis-dependant pathway, independent
of SP1.
Immunofluorescence staining of SP1 was significantly increased in miR-29c inhibited RTCs
(p = 0.003, Figure 4B). In contrast, SP1 was inhibited in miR-21/mir-150 transfected renal cells (Figure 4B).
COL1A1 protein levels increased in all conditions and did not correlate with SP1 levels (Figure 4B).
4. Discussion
We have shown that urinary exosomes are the best source of urinary miRNA biomarkers in LN
patients. The comparison between urinary pellet and exosomes showed a better yield of miRNAs
from exosomes than from the cellular pellet. One possible explanation is the fact that inside urinary
exosomes, miRNAs can be preserved and protected from the RNase activity in the kidney urinary
tract [42].
We simultaneously measured five urinary exosomal MiRNAs, previously associated with fibrosis:
miR-21 and miR-200a, which directly regulate multiple collagen isoforms and extracellular matrix
components via TGFβ pathway [23]; and miR-410, miR-29c, and miR-150, which have been reported in
renal fibrosis in LN [24–26]. Of those, we only found miR-21, miR-150, and miR-29 to be differentially
expressed in urinary exosomes from patients with LN and to correlate with chronicity scores in the renal
biopsy. High degree of fibrosis was characterised by a significant upregulation of miR-21, miR-150,
and miR-29c downregulation.
FibromiRs are essential downstream components of both fibrogenic and fibrosis-suppressive
signalling pathways, and changes in their expression directly affect the biological response following
activation of these pathways [3]. As a consequence, several reports studied them separately, as
individual miRNAs assay. However, fibrogenesis results from alterations or imbalances in multiple
interconnected molecular pathways [43]. We report here, for the first time, a multimarker urinary
exosomal miRNA panel to diagnose the degree of chronicity in lupus nephritis patients at flare using
the CombiROC tool. This methodology is available as an easy-to-use web application to accurately
determine optimal combinations of markers and takes advantage of combinatorial analysis and
ROC curves [41]. It has been used to screen multimarker signatures for autoimmune hepatitis [44],
biomarker panels for cancer [45], and Parkinson disease [46]. In our study, the individual miRNAs
discriminate low from moderate-high chronicity in lupus nephritis; however, their combination as
multiple biomarker signatures showed the best specificity and sensitivity profile to detect early fibrosis.
In addition, our results also showed the presence of the miR-29c/miR-150/miR-21 combinatory panel
as a predictor of progression to ESRD and its predictive value was superior to routine conventional
biomarkers such as creatinine and eGFR. If these data are confirmed in larger studies, this biomarker
panel could be used as a diagnostic marker of renal fibrosis and a prognostic biomarker of progression
to ESRD.
The exact mechanism of fibrosis in LN is unknown, but the persistence of wound-healing processes
with prolonged production of growth factors, fibrogenic cytokines, and proteolytic enzymes, leading
to increased synthesis and degradation of the extracellular matrix [47] seems to play a role. Previous
studies in LN focused on the fibrotic role of miR-150 by targeting SOCS1, a negative regulator of
profibrotic proteins [26] and miR-29c downregulation [25]. Upregulation of miR-21 also induces
collagen and other extracellular matrix components via the TGFβ/Smad3 pathway [48]. Our pathway
analysis identified VEGFA and SP1 as common targets of miR-21, miR-150, and miR-29c. The expression
of VEGFA, SP1, and profibrotic proteins was then measured in the LN kidney biopsies. As expected,
COL1A1 and COL4A1 staining increased progressively and correlated with the renal chronicity index.
This is not surprising, since renal interstitial fibrosis is the result of an increase in important ECM
components, such as collagens [49]. Although it is well-known that down regulation of VEGF is related
with worse prognosis in lupus nephritis [50], we did not find differences in the VEGFA staining in the
CI subgroups. However, SP1 was found to be increased in patients with low and mainly moderate CI,
but significantly decreased in patients with high CI.
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We next evaluated in vitro the physiologic relevance of the study miRNAs in promoting fibrosis.
Transfection of PTCs with miR-150 and miR-21 mimics, significantly suppressed SP1 production while
inducing an increase of profibrotic molecules after TGFβ stimulation. The same condition in mesangial
cells mirrored the results obtained in the tubular cells suggesting a profibrotic effect of these miRNAs
through the Smad3/TGFβ pathway, independent of SP1. Transfection of PTCs with a miR-29c inhibitor
significantly increased the production of SP1, profibrotic molecules, and Smad3. In mesangial cells,
there was a moderate production of COL4A1, TGFβ, and Smad3, whereas SP1 and COL1A1 were
not significantly expressed. Data suggest a role for miR-29c in the production of fibrosis in tubular
epithelial cells through the SP1/Smad3/TGFβ pathway.
Growing evidence demonstrates that SP1 plays an important regulatory role for the expression of
several genes relevant to fibrosis, including TGFβ, vascular endothelial growth factor, type I collagen,
and downstream targets of TGFβ, such as matrix metalloproteinases, plasminogen activator inhibitor-1,
and fibronectin [51]. Several studies have shown that SP1 mediates TGFβ fibrogenic factor through
cooperation with Smads proteins and is an essential mediator for the production of type I collagen
induced by miR-29c downregulation [52]. SP1 has been shown in the glomeruli and proximal tubules
of a broad spectrum of human glomerulonephritides, being more prominent in the glomeruli of
secondary proliferative GNs [51]. It has been shown that SP1 mediates MCP-1 expression in murine
podocytes and could also be implicated in the induction of renal injury through the attraction of
macrophages [53]. Therefore, Sp1 overexpression in glomeruli of proliferative GNs may be as a result
of the inflammatory process.
Our data suggest that miR-150, miR-21, and miR-29c play an important role in renal fibrogenesis
by increasing the synthesis of profibrotic molecules through several mechanisms. We demonstrated
an early role of miR-29c and SP1 in regulating collagen production in tubular epithelial cells, while
miR-150 and miR-21 expression contribute to the maintenance and amplification of the fibrotic process
leading to ESRD through a Smad3/TGFβ pathway independent of SP1 at later stages (Figure 4C).
In summary, we have demonstrated that a urinary exosomal multimarker panel formed by
miR-21, miR-150, and miR-29c provide a non-invasive method to detect early renal fibrosis and predict
disease progression in LN patients. Although the exact molecular basis of the three urinary exosomal
miRNAs during renal injury remains unclear, we have identified relevant pathways in the LN renal
fibrosis mechanism, and a better understanding of the pathogenesis could contribute to develop new
therapeutic approaches.
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